Optimal Duration of Daily Antituberculosis Therapy before Switching to DOTS Intermittent Therapy to Reduce Mortality in HIV Infected Patients: A Duration-Response Analysis Using Restricted Cubic Splines

Table 1

Baseline characteristics and multivariable analysis of factors associated with mortality in 520 HIV infected patients with tuberculosis who completed two months of antituberculosis therapy in Anantapur, India.

	Baseline characteristics	Mortality risk
	(%)	aHR (95% CI)
Female	184 (35.4)	0.80 (0.54–1.20)
Homeless	15 (2.9)	1.98 (0.77–5.09)
Illiteracy	293 (56.3)	1.40 (0.94–2.09)
Sputum smear positive	110 (21.2)	1.29 (0.87–1.91)
Disseminated TB	27 (5.2)	1.80 (0.94–3.45)
ART initiation
Before ATT	137 (26.3)	0.81 (0.53–1.24)
Within 2 months of ATT	229 (44)	0.37 (0.23–0.58)
Not initiated	154 (29.6)	1 (reference)
Age (years)	35.5 (30–42)^*	Figure 4
CD4 count (cells/mm^3)	136 (71–242)^*	Figure 4
Serum albumin (g/dL)	3 (2.5–3.5)^*	Figure 4
Daily ATT (days)	36 (31–48)^*	Figure 3

Median (interquartile range). ART: antiretroviral therapy; ATT: antituberculosis therapy; aHR: adjusted hazard ratio; CI: confidence interval; TB: tuberculosis. Continuous variables (age, CD4 lymphocyte counts, serum albumin, and number of days on daily ATT) were modeled using restricted cubic splines and their adjusted hazard ratios are presented graphically in Figures 3 and 4.